George Medicines Signs Korea Deal to Commercialize GMRx2
LONDON, UK, March 11, 2026 George Medicines, a late-stage biopharmaceutical company focused on cardiometabolic diseases, has announced an exclusive...
Cardiovascular drug development
Advertisement
Pulse Biosciences Secures FDA IDE Approval to Launch Clinical Trial of nsPFA Cardiac Surgery System for Atrial Fibrillation
Hayward, CA – September 9, 2025 – Pulse Biosciences, a pioneer in bioelectric medicine and nanosecond pulsed field ablation...
Novartis to Acquire Tourmaline Bio, Expanding ASCVD Pipeline
September 9, 2025 – Basel – In a move set to strengthen its cardiovascular disease portfolio, Novartis announced an...
Advertisement
